Consistent with previous findings, TPX2 overexpression enhanced CD8+ T cell-mediated antitumor immunity and improved the efficacy of anti-PD-1 therapy in a hepatocellular carcinoma patient-derived xenograft mouse model [51]. This evidence concerns the gene CD8A and hepatocellular carcinoma.